Medication eluting devices for the field of OBGYN (MEDOBGYN): 3D printed biodegradable hormone eluting constructs, a proof of concept study

Karthik Tappa  
Washington University School of Medicine in St. Louis

Udayabhanu Jammalamadaka  
Washington University School of Medicine in St. Louis

David H. Ballard  
Washington University School of Medicine in St. Louis

Todd Bruno  
Louisiana State University at Shreveport

Marissa R. Israel  
Saint Louis University Hospital

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Tappa, Karthik; Jammalamadaka, Udayabhanu; Ballard, David H.; Bruno, Todd; Israel, Marissa R.; Vemula, Harika; Meacham, J. Mark; Mills, David K.; Woodard, Pamela K.; and Weisman, Jeffery A., "Medication eluting devices for the field of OBGYN (MEDOBGYN): 3D printed biodegradable hormone eluting constructs, a proof of concept study." PLoS One. 12,8. e0182929. (2017).  
https://digitalcommons.wustl.edu/open_access_pubs/6263

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Karthik Tappa, Udayabhanu Jammalamadaka, David H. Ballard, Todd Bruno, Marissa R. Israel, Harika Vemula, J. Mark Meacham, David K. Mills, Pamela K. Woodard, and Jeffery A. Weisman
RESEARCH ARTICLE

Medication eluting devices for the field of OBGYN (MEDOBGYN): 3D printed biodegradable hormone eluting constructs, a proof of concept study

Karthik Tappa¹, Udayabhanu Jammalamadaka¹, David H. Ballard¹, Todd Bruno², Marissa R. Israel³, Harika Vemula⁴, J. Mark Meacham⁵, David K. Mills⁶, Pamela K Woodard¹, Jeffery A. Weisman*¹

¹Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, United States of America, ²Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, Shreveport, Louisiana, United States of America, ³Department of Pharmacy, St. Louis University Hospital, St. Louis, Missouri, United States of America, ⁴Pharmaceutical Sciences and Chemistry, University of Missouri- Kansas City, Kansas City, Missouri, United States of America, ⁵Department of Mechanical Engineering & Materials Science, Washington University, St Louis, Missouri, United States of America, ⁶Department of Biomedical Engineering, Louisiana Tech University, Ruston, Louisiana, United States of America, ⁷Department of Anesthesiology, Washington University School of Medicine, St Louis, Missouri, United States of America

* jweisman@wustl.edu

Abstract

3D printing has the potential to deliver personalized implants and devices for obstetric and gynecologic applications. The aim of this study is to engineer customizable and biodegradable 3D printed implant materials that can elute estrogen and/or progesterone. All 3D constructs were printed using polycaprolactone (PCL) biodegradable polymer laden with estrogen or progesterone and were subjected to hormone-release profile studies using ELISA kits. Material thermal properties were tested using thermogravimetric analysis and differential scanning calorimetry. The 3D printed constructs showed extended hormonal release over a one week period. Cytocompatibility and bioactivity were assessed using a luciferase assay. The hormone-laden 3D printed constructs demonstrated an increase in luciferase activity and without any deleterious effects. Thermal properties of the PCL and hormones showed degradation temperatures above that of the temperature used in the additive manufacturing process—suggesting that 3D printing can be achieved below the degradation temperatures of the hormones. Sample constructs in the shape of surgical meshes, subdermal rods, intrauterine devices and pessaries were designed and printed. 3D printing of estrogen and progesterone-eluting constructs was feasible in this proof of concept study. These custom designs have the potential to act as a form of personalized medicine for drug delivery and optimized fit based on patient-specific anatomy.
Introduction

Major advances in biomedical engineering have led to new patient-specific technologies which treat diseases using biocompatible materials as controlled drug delivery systems. Additive manufacturing techniques, including Fused Deposition Modeling (FDM) 3D printing, boast high speed, accuracy, affordability, and feasibility leading to its increased use in medicine and biotechnology. Because of its rapid production and customizability, 3D printing has been used to construct prostheses, human tissues, medical devices, and surgical implants for dental and orthopedic applications [1–5].

Estrogens are available in various formulations and are administered via different routes such as intramuscular, subcutaneous, intravenous, transdermal, vaginal, and oral. Estrogen, progesterone, or combination formulations are variously used for contraception, regulation of the menstrual cycle, hormone replacement therapy (HRT), and vaginal atrophy among others. These drugs are delivered in a variety of forms. For example, extended steady-state release subcutaneous HRT implants are usually in the shape of a small pellet, made by fusing pure crystals of hormones, and are available at doses of 50–100 mg. Intrauterine devices (IUDs) are considered excellent long-term birth control because of their safety, efficacy, and ease of use [6]. These are small T-shaped devices, made of flexible plastic, are placed directly into the uterus, releasing small amounts of a progestin for up to 12 years [7]. Pessaries are medical devices used to treat pelvic organ prolapses by providing structural support to the uterus, vagina, bladder, and rectum [8], and are typically used in conjunction with local estrogen therapy. These devices are made in different sizes and designs that are subject to patient needs, anatomy, and physician preference [9].

Currently available obstetric and gynecologic implants are bulk manufactured with fixed doses, whereas every individual is unique, requiring different doses of hormones. Differences in IUD shapes and dosage concentrations leads to ectopic pregnancies, pelvic inflammatory disease, uterine perforations [10–11]. Commercially available IUDs cannot account for the differences between individuals. Bioactive 3D printing of IUDs and pessaries has the potential to provide patient-specific devices while delivering extended release hormones. The purpose of this study is to engineer customizable and biodegradable 3D printed implant material that can elute estrogen or progesterone.

Materials and methods

Materials

The Polycaprolactone (PCL) pellets used for filament extrusion were purchased from Sigma-Aldrich (St. Louis, MO). Hormones Estrone (E1) (SLE 1048), Estradiol (E2) (CAS 57-63-6) and Estriol (E3) (CAS 50-27-1), and Progesterone (P) (CAS 57-83-0) were purchased from PCCA, Houston, TX. Cell culture plates and other lab plastics were purchased from MidSci, St. Louis, MO. Rosewell Park Memorial Institute Medium (RPMI), Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), and penicillin-streptomycin-amphotericin (PSA) antibiotics were obtained from Life Technologies, Carlsbad, CA. Estrogen receptor luciferase reporter T47D stable cell line (Sl-0002-NP) was purchased from Signosis, Inc. (Santa Clara, CA). KJLC 705 silicone oil used for coating the beads before extrusion was purchased from Kurt J. Lesker Company (Jefferson Hills, PA). The 3D printing equipment consists of an ExtrusionBot extruder (ExtrusionBot, LLC Phoenix, AZ) and a MakerBot Replicator 5th Generation Desktop 3D printer (Makerbot Industries Brooklyn, NY). The nanodrop spectrophotometer was from Thermo Scientific (Wilmington, DE). Solidworks 2015 student edition 3D computer aided design (CAD) program Dassault Systèmes (Waltham, MA) and Blender.
Fabricating hormone loaded scaffolds

PCL thermoplastic pellets were used for loading hormones due to its low melting temperatures, excellent biodegradability and biocompatibility. These pellets were coated with the calculated amount (1% w/w) of hormones and extruded as filaments of 1.75 mm diameter, which were used in Makerbot 1st generation desktop 3D printer to print customized implant materials.

Coating pellets with hormones. To enable an even dispersion of hormones on the surface of the commercially available PCL pellets, an oil coating method was used. To surface coat pellets, KJL 705 silicone oil was chosen because of its thermal stability at elevated temperatures. 15 μl of silicone oil was added to a 20 gm batch of pellets which were then vortexed to evenly and completely coat the pellets. Once vortexed, the pellets were transferred to another container to avoid loss of drug powder due to sticking to the surface of the oil coated mixing container. After switching containers, the calculated amount of hormones in powdered form was added and the mixture was vortexed again. This process is illustrated in Fig 1.

Extruding hormone loaded filaments. An ExtrusionBot filament extruder was used to extrude coated pellets. Since the 3D printer used requires a 1.75 mm diameter filament to print, a metal die of the same diameter was used to extrude the filament. Each 20 gm batches of E1, E2, E3, and progesterone were extruded at 90–100˚C.

Optimizing 3D printing parameters. 3D printer based on FDM is a very delicately balanced machine. If filament-extrusion temperature, the speed of extrusion and speed of the printer-head are not coordinated, the printing process does not yield constructs of the required shape. An optimized process also involves complex integration between hardware, software and material properties. Primary trials revealed that the printer-head temperature and filament feed rate have a direct influence on the material flow for the fabrication of the scaffolds. For this reason, optimization of printing parameters for PCL was focused mostly on printer-head temperature and filament feed rate. The minimum temperature of the printer-head that could print PCL was determined, and the filament extruding rate was adjusted accordingly.

On the MakerBot 1st generation 3D printer, PCL prints at a lowest temperature of 100˚C, and to compensate for this, the printer-head speed was reduced from a default 40 mm/s to 10 mm/s and increase the filament feed rate from a default 18 mm/s to 23 mm/s. All E1, E2, E3 and progesterone constructs were printed at 110˚C at a printer-head speed of 10 mm/s and a constant filament-feed rate of 23 mm/s.

Scaffolds design and fabrication

All 3D models including IUDs, meshes, and pessaries were designed using Solidworks 2015 CAD software. Discs of 5 x 1 mm dimensions were printed for drug elution testing and in vitro
cell cultures. IUDs and pessaries of different dimensions and shapes were also designed and printed using the extruded filaments.

Scaffold characterization

The 3D printed hormonal scaffolds were subjected to physical and bioactive testing. Surface morphology of the constructs was studied using SEM. Thermal properties were evaluated.
using TGA and DSC. Crystalline and amorphous states of the constructs were analyzed using XRD. ELISA kits were used to study hormonal release from scaffolds, and Luciferase assay was conducted to test the bioactivity of the hormonal discs.

**Morphology.** Extruded filaments and printed discs of different hormones were subjected to SEM using S4800 Field Emission SEM, HITACHI (Schaumburg, IL) at different magnifications. Construct surface were coated with a thin film of gold before imaging to make them conductive.

**Thermal properties.** Given that polymers undergo heating during 3D printing, thermal degradation behavior of polymer, hormones and the 3D printed constructs were studied using TA Instrument Q5000 IR. The samples were tested using ramp method. Samples were heated from ambient temperature to 500°C at a rate of 20°C/min and changes in sample weight were measured. Changes in melting temperatures ($T_m$) and glass transition temperatures ($T_g$) of polymers due to addition of hormones were tested using DSC. Samples were heated from -80°C to 130°C at a rate of 10°C/min. Energy input (heat flow) was measured as a function of temperature in this analysis. Both analyses were carried out in a nitrogen environment.

**X-ray diffraction.** Crystalline and amorphous properties were analyzed using XRD. Rigaku DMaxB instrument was operated at 35K and 30mA to produce radiation from Copper. Diffractions were measured within the range of scattering angles ($2\theta$) of 10° to 50° with dwell time of 2 min.

**Absolute quantification of hormones using tandem MS/MS analysis.** An LC-MS/MS method was developed for the separation and quantification of different hormones in the scaffolds using mass spectrometry. A gradient elution method was employed with solvent A (HPLC water and 0.1% formic acid) and solvent C (acetonitrile and 0.09% formic acid) as the mobile phase solvents with a total run time of 14 min and flow rate of 0.3 mL/min. The elution profile starts with 10% solvent C ramped to 60% in 8 min and 100% in next 2 min, followed by post-equilibration with solvent C to 10% for 4 min. The UV detector was set at 280 nm. A multiple reaction monitoring method was developed with 1mM standard solutions of E1, E2, E3 using the signature transitions for each analyte- E1, E3 (271.3/133.0) and E2 (255.0/159.0). Method development included validation for accuracy, specificity, sensitivity, determination of response linearity, limit of detection (LOD), lower limit of quantification (LLOQ) and possible matrix effects and carryover.

Samples were prepared by suspension and extraction of the discs in diethyl ether. The dried extract is resuspended in 50 uL of solvent A and analyzed by LC-MS.

**Hormone elution profile.** To calculate the amount of hormone eluting from the constructs, an elution study was conducted. Saline was used for sample collection. Samples from E2 and E3 were collected at periodic intervals for a week. These collected samples were analyzed using appropriate ELISA kits. From the ELISA pilot studies, it was determined that the concentration of E2 eluting from the scaffolds was above the maximum detection level and all measurements were near saturation. A ten-fold dilution of the E2 samples and ELISA was performed. E3 samples had absorbance values within the ELISA detection range and were not diluted. The SpectraMax M2e multimode microplate reader was used to read the 96 well plates absorbance values. From the absorbance values of standards, the four parameter logistic (4PL) nonlinear regression model was drawn, and concentrations of unknown samples were back calculated. For all the assays, the absorbance values at 405 nm were measured and recorded.

**Hormonal activity.** The hormonal activity of E2 in the 3D printed scaffolds was assessed as follows. Plain PCL pellets, saline and different concentrations of E2 were used as controls. Extruded filaments and 3D printed discs were used as unknowns. Before these scaffolds were seeded, 90% confluent endometrial cells were detached from the culture tubes and suspended in RPMI medium. Each well was filled with 10 μL of suspension and incubated for 24 hours for
attachment. Scaffolds were added to these wells and incubated for another 16 hours. Lysis buffer was added to each well and incubated for two minutes. In a new 96 well plate, 20 μl of this lysate was transferred, and 100 μl of luciferase substrate is added. Optical density of each well was immediately read using a luminometer.

Statistical analysis

For the ELISA assay, three samples of each batch were tested and averaged for reproducibility. Standard deviations of the means were calculated and mentioned in the elution profile graphs as error bars. For the in-vitro study, measurements from five wells of each group were averaged. A one-way ANOVA was conducted to analyze the significant difference between the means among the groups. The standard deviation of the means was calculated and represented as error bars in the graphs.

Results

PCL pellets were successfully coated with E1, E2, E3 and progesterone hormones. Each 20 gm batch of 1.75 mm diameter filaments were extruded, and the required constructs were successfully printed. Fig 2 shows images of PCL constructs printed with and without hormones using
the Makerbot 3D printer. Constructs containing a combination of hormones can be printed using this technique. Fig 2D shows a donut shaped pessary printed with unloaded polylactic acid (PLA) filament (red) and with PCL filament (white) loaded with E2 hormone. Fig 3 shows of surgical mesh printed using PCL-Estrogen and an IUD, rod shaped implant 3D printed using Progesterone loaded PCL filaments.

**Scanning electron microscopy (SEM)**

SEM was used to study the surface morphology of the coated pellets, filaments, and printed discs. Fig 4 shows the SEM images of estrogen hormones E1, E2, and E3. All these hormones contain irregularly shaped particles of varied sizes. The estimated largest size of these particles was around 5 μm. Filaments extruded from ExtrusionBot were
cylindrical in shape and had a smooth external surface. The SEM image in Fig 5 shows hormone loaded PCL filaments extruded using the ExtrusionBot filament extruder.

Extruded filaments were used in Makerbot 3D printer to print discs of 5 mm x 1 mm dimensions. Figs 6, 7A and 7B shows all 3D printed discs used for ELISA and cell culture at 25X magnification. These images exhibit layers of filaments comprising cylindrical shape with 300 μm in diameter and the sintering between the layers. On further magnification, hormone particles were seen on the surfaces of these discs. Figs 6, 7C and 7D shows E1, E2, E3 and Progesterone particles on the surfaces of the discs.

Fig 6. SEM images of discs. (A, C) PCL-E1 Discs, (B, D) PCL-E2 Discs.
https://doi.org/10.1371/journal.pone.0182929.g006
Thermal properties

All the hormones started thermal degradation at 190–240°C and PCL degradation was observed to start at 280°C (Fig 8). The estradiol thermogram shows a 4% reduction in weight at 100°C suggesting the presence of residual moisture in the estradiol sample.

While the hormones initially had degradation temperatures ranging from 190–240°C, incorporating them in PCL matrix rendered both hormones and PCL more thermally stable. Thermal degradation of all the 3D printed composites containing PCL matrix and hormones had degradation starting at 310°C (Fig 9).

Differential scanning calorimetry results suggest the changes in $T_g$ and $T_m$ of the polymer composites was not pronounced as shown in Fig 10. Small changes in $T_g$ were observed in the composites when compared with PCL. Glass transition temperature of PCL was observed to be at -62.8°C while the composites’ $T_g$ ranged from -64.9°C to -63.3°C. For PCL, $T_m$ was observed to be 61.7°C and the composites had melting temperatures ranging from 65.2°C to 58.5°C.

X-ray diffraction

Diffractograms of PCL and hormones show their amorphous and crystalline phases (Fig 11). Crystalline phases in PCL are attributed to the strong peaks at 21.4° and 23.8°. Amorphous scatter of PCL is observed over a range of 14° to 25°. Crystalline scatter of estriol is seen at 13.2° and 20.5°. Multiple crystalline scatter peaks were observed for estradiol at 13.4°, 15.9°, 18.4°, 20.6°, 22.8°, and 26.8°. Peaks observed at 14.5°, 15.2°, 17.4°, 18.4°, and 20.2° for estrone.
are due to the crystalline phase in the powder. Crystalline scatter peaks for progesterone were observed at 10.7°, 12.8°, and 17°. For all the hormones, amorphous scatter was seen as a large bump at 2θ ranging from 10° to 30°. Diffractograms of PCL-hormone composites are shown in Fig 12. All the diffractograms had the same pattern as PCL polymer.

**LC-MS/MS detection of hormones from implants**

Using LC-MS, successful detection, separation and absolute quantification of different hormones (E1, E2, E3, and Progesterone) were performed, given the same transitions (271.3/133.0) for E1 and E3 (S1 Fig). The elution of hormones from the column is based on the hydrophilicity of analyte with E3 eluting first followed by E2 and E1. The results are further confirmed by comparing these findings to their respective peaks in UV chromatogram at 260nm. The concentrations of different hormones in the constructs were also determined with a control (negative) where no analytes were detected (S2 Fig).

**Quantification through ELISA**

Preliminary studies showed the release of hormones were in nanograms concentration. A ten-fold dilution of the samples was done to meet the ELISA kits detection range. Samples were collected, one for each day. For the first two days, 35% of total hormone was released from the scaffolds. 

Fig 13 shows the concentration of hormone E2 released over a period of one week. A total of 215 ng/mL of the cumulative concentration of E2 hormone was released at the end of day
seven. Even after seven days, small quantities of hormone release within the working concentration (2 ng/mL - 5 ng/mL) were measured. All the hormone loaded discs were 3D printed at 300 μm resolution. Preliminary tests showed the release of E3 hormones from the constructs were within the detectable range of the ELISA kits. For the first two days, 46% of total E3 hormone was released from the scaffolds. On day seven, 1.3 ng/mL hormone was released.

Fig 13 also shows the cumulative concentration of E3 released from PCL scaffolds for seven days. A standard graph plotted from the known concentration was used to yield a four parameter logistic curve. E3 release increased during the first four days, after which hormonal elution was steady and extended. A total of 118 ng/ml (cumulative concentration) of E3 hormone was released by the end of day four.

In vitro assay

Fig 14 shows the Relative Light Unit (RLU) values of luciferase activity in response to estrogen stimuli. Five wells of each group were tested and ANOVA was conducted. The difference between the control cells and control PCL pellets was not statistically significant (p ≤ 0.05), indicating that the PCL pellets are biocompatible and do not promote any estrogen induced pathways. The group containing E2 showed a robust increase in RLU values when compared to groups without inducing agent, indicating the presence of bioactive compounds in the fabricated constructs. Wells containing 100 pg/ml concentration of E2 showed a total of 84.6% more luciferase activity. Luciferase activity for extruded filaments (1 cm length) and 3D printed discs (5 mm X 1mm) increased by 80.85% and 74.9%, respectively, when compared to the control cells activity.

Fig 9. TGA thermograms of PCL-hormones composites.
https://doi.org/10.1371/journal.pone.0182929.g009
Discussion

Fused deposition modeling was used to fabricate hormone loaded biodegradable implant materials. PCL pellets were coated with estrogen (E1, E2, E3) and progesterone, then filaments of required dimensions were successfully extruded. With these bioactive enhanced filaments, constructs of relevant designs were fabricated using 3D printing. SEM images showed extruded filaments were smooth and cylindrical in nature. Thermal properties of the PCL, hormones and composites indicate that 3D printing can be achieved well below their degradation temperatures. Given that thermal degradation of both the hormones and PCL polymer began at 190˚C or greater and 3D printing of all the constructs was done at 130˚C, it can be inferred that both hormones and polymer were not thermally degraded during the 3D printing process. Additionally, the transitional temperatures of the 3D printed constructs were not greatly affected due to the presence of hormones. The absence of amorphous scatter (other than PCL) in the diffractograms may signify that changes in crystalline phases of hormones did not occur. As the composites had low concentration of 1% w/w, it is possible that the x-rays could not interact with hormones to cause any diffraction or the heating during the 3D printing process may have affected their crystalline phases.

The chromatographic peaks for hormones E1, E2, E3, and progesterone show the presence of bioactive compounds in 3D printed constructs. The study of release kinetics using ELISA assay showed that the hormones E2 and E3 were released at a steady rate from the scaffolds over a short period. In vitro assays conducted on estrogen receptor luciferase reporter cell lines show that the fabricated scaffolds were biocompatible. Groups enhanced with hormones showed robust luciferase activity, indicating the presence of a bioactive inducing substance (E2) in the scaffolds.
Bioactive 3D printing has been the focus of several in vitro investigations to deliver antibiotics and chemotherapeutics. Weisman et al. [12] used fused depositional modeling to create 3D-printed gentamicin- and methotrexate-laden constructs. The drug-laden bioactive constructs showed antimicrobial and tumor-inhibiting effects, both with favorable elution profiles. In another study, this concept was implemented in antibiotic and chemotherapeutic impregnated catheters and showed similar in vitro results [13]. Ballard et al. [14] used fused deposition modeling to create customized surgical meshes. In that study, gentamicin-laden meshes inhibited bacterial growth compared to none by control 3D-printed surgical meshes.

There have been few studies that use 3D printing for implications in obstetrics and gynecology. Tudela et al. [15] used prenatal ultrasound measurements of cervical length and radius to fabricate custom 3D printed cerclage pessaries. Hakim et al. [16] fabricated vaginal stents and dilators of customizable sizes and shapes from computed tomographic-acquired data from commercial products. In radiation oncology, 3D printing has been used in a small number of patients to fabricate custom vaginal cylinders for vaginal brachytherapy [17–19]. Sethi et al. [19] reported 3D printing custom vaginal applicators for brachytherapy in patients with
unique and postsurgical vaginal anatomy. Finally, the creation of bioprosthetic ovaries in mice has been facilitated using 3D printing. Laronda et al. [20] 3D printed porous gelatin scaffolds with stiffness to mimic ovarian tissue (based on reference standards) and pore size and morphology to accommodate ovarian follicles. After substantiating their finding \textit{in vitro}, they implanted the 3D printed ovarian-like implants into mice with oophorectomies. These scaffolds were populated with ovarian follicles in various stages of maturity. Over time, the

![Fig 12. XRD diffractograms of PCL-hormones composites.](https://doi.org/10.1371/journal.pone.0182929.g012)

![Fig 13. Cumulative concentration of E2 and E3 released from PCL composite discs (mean ± SD, n = 3).](https://doi.org/10.1371/journal.pone.0182929.g013)
development of these bioprosthetic ovaries demonstrated folliculogenesis and development of blood vessels throughout the scaffolds. Further, three of seven mice with 3D printed bioprosthetic ovaries demonstrated fertility and bore offspring [20].

The present study offers the first data to show hormone-laden 3D printed constructs. While the potential benefits, pitfalls, and clinical correlates for the estrogen and/or progesterone-eluting constructs fabricated in this study are unclear, the ability to impregnate 3D printed constructs with bioactive hormones portends new possibilities in additive manufacturing of implants and devices.

The resolution of the 3D printed constructs can be changed by altering the layer height of the deposited filament. With decrease in layer height of the filament, surface area of the construct increases and should, in turn, increases the hormonal release.

The ability to 3D print estrogen and/or progesterone-loaded biodegradable implants holds great potential in personalized medicine. Using these methods, IUDs, and pessaries could be tailored to a patient’s specific needs in aspects of the unique anatomy of the individual, hormone dosage and period of hormone therapy.

Supporting information

S1 Fig. LC-MS/MS chromatogram. LC-MS/MS chromatogram of the standard hormone solutions showing the E1, E2, E3 and Progesterone peaks. (TIF)

S2 Fig. Chromatographic LC/MS analysis. Chromatographic LC/MS analysis of the 3D printed constructs with control, E1, E2, E3 and Progesterone hormones. (TIF)
SI File. Supplementary raw data.
(XLSX)

Author Contributions

Conceptualization: Karthik Tappa, Udayabhanu Jammalamadaka, David K. Mills, Jeffery A. Weisman.

Data curation: Karthik Tappa, Udayabhanu Jammalamadaka, David H. Ballard, Harika Vemula, Jeffery A. Weisman.

Formal analysis: Karthik Tappa, Udayabhanu Jammalamadaka, David H. Ballard.

Funding acquisition: Karthik Tappa.

Investigation: Karthik Tappa, David H. Ballard, Marissa R. Israel, Pamela K Woodard.

Methodology: Karthik Tappa, Udayabhanu Jammalamadaka, Harika Vemula, J. Mark Meacham, Jeffery A. Weisman.

Project administration: Jeffery A. Weisman.

Resources: Marissa R. Israel, Harika Vemula, David K. Mills, Pamela K Woodard.

Software: Karthik Tappa.

Supervision: David H. Ballard, Marissa R. Israel, Pamela K Woodard, Jeffery A. Weisman.

Validation: David H. Ballard, Todd Bruno, Marissa R. Israel, Pamela K Woodard, Jeffery A. Weisman.

Visualization: Todd Bruno, David K. Mills, Jeffery A. Weisman.

Writing – original draft: Karthik Tappa, Udayabhanu Jammalamadaka, Jeffery A. Weisman.

Writing – review & editing: David H. Ballard, Todd Bruno, Marissa R. Israel, Harika Vemula, J. Mark Meacham, David K. Mills, Pamela K Woodard, Jeffery A. Weisman.

References

1. Banks J. Adding value in additive manufacturing: Researchers in the United Kingdom and Europe look to 3D printing for customization. IEEE Pulse. 2013; 4(6):22–6. https://doi.org/10.1109/MPUL.2013.2279617 PMID: 24233187

2. Mertz L. Dream it, design it, print it in 3-D: What can 3-D printing do for you? IEEE Pulse. 2013; 4(6):15–21. https://doi.org/10.1109/MPUL.2013.2279616 PMID: 24233186

3. Gross BC, Erkal JL, Lockwood SY, Chen C, Spence DM. Evaluation of 3D printing and its potential impact on biotechnology and the chemical sciences. Anal Chem. 2014; 86(7):3240–53. https://doi.org/10.1021/ac403397r PMID: 24432804

4. Cui X, Boland T, D’Lima DD, Lotz MK. Thermal inkjet printing in tissue engineering and regenerative medicine. Recent Pat Drug Deliv Formul. 2012; 6(2):149–55. PMID: 22436025

5. Duan B, Hockaday LA, Kang KH, Butcher JT. 3D bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels. J Biomed Mater Res A. 2013 May; 101(5):1255–64. https://doi.org/10.1002/jbm.a.34420 PMID: 23015540

6. Kailasam C, Cahill D. Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. Patient Prefer Adherence. 2008 Jan; 2:293–302. PMID: 19920976

7. Programme UND, Fund UNP, Organization WH, Bank W, Research SP of, Reproduction D and RT in H. Long-term reversible contraception. Contraception. Elsevier; 2017 Jan 19; 56(6):341–52.

8. Jelovsek JE, Maher C, Barber MD. Pelvic organ prolapse. Lancet. 2007. p. 1027–38.

9. Roehl B, Buchanan EM. Urinary incontinence evaluation and the utility of pessaries in older women. Care Manag J. 2006 Jan; 7(4):213–7. PMID: 17194058
10. Weisman JA, Nicholson JC, Tappa K, Jammalamadaka U, Wilson CG, Mills DK. Antibiotic and chemotherapeutic enhanced three-dimensional printer filaments and constructs for biomedical applications. Int J Nanomedicine. 2015 Jan; 10:357–70. https://doi.org/10.2147/IJN.S74811 PMID: 25624758

11. Espey E, Ogburn T. Long-term reversible contraceptives: intrauterine devices and the contraceptive implant. Obstetrics and gynecology. 2011 March; 117(3):705–719. https://doi.org/10.1097/AOG.0b013e31820ce2f0 PMID: 21343774

12. Edelman D, Berger G, Keith L. Intrauterine Devices and their complications. Dordrecht: Springer Netherlands; 1979. 263 p.

13. Weisman JA, Jammalamadaka U, Tappa K, Nicholson JC, Ballard DH, Wilson CG, et al. 3D printing antibiotic and chemotherapeutic eluting catheters and constructs. J Vasc Interv Radiol. Elsevier; 2015 Feb 2; 26(2):S12.

14. Ballard DH, Weisman JA, Jammalamadaka U, Tappa K, Alexander JS, Griffen FD. Three-dimensional printing of bioactive hernia meshes: In vitro proof of principle. Surgery. 2017 Jun; 161(6):1479–81. https://doi.org/10.1016/j.surg.2016.08.033 PMID: 27726915

15. Tudela F, Kelley R, Ascher-Walsh C, Stone JL. Low Cost 3D Printing for the Creation of Cervical Cervical Pessary Used to Prevent Preterm Birth. Obstet Gynecol. 2016 May; 127:154S.

16. Hakim J, Oluyemisi A, Buskmlller C, Krishnamurthy R, Cohn W, Dietrich JE. Innovative Use of 3D Printers in Gynecology. J Pediatr Adolesc Gynecol. Elsevier; 2015 Apr; 28(2):e67.

17. Cunha JAM, Mellis K, Sethi R, Siauw T, Sudhyadhom A, Garg A, et al. Evaluation of PC-ISO for customized, 3D Printed, gynecologic 192-Ir HDR brachytherapy applicators. J Appl Clin Med Phys. 2015 Jan 8; 16(1):5168. https://doi.org/10.1120/jacmp.v16i1.5168 PMID: 25679174

18. Ricotti R, Vavassori A, Bazani A, Ciardo D, Pansini F, Spoto R, et al. 3D-printed applicators for high dose rate brachytherapy: Dosimetric assessment at different infill percentage. Phys Medica. 2016 Dec 1; 32(12):1698–706.

19. Sethi R, Cunha A, Mellis K, Siauw T, Diederich C, Pouliot J, et al. Clinical applications of custom-made vaginal cylinders constructed using three-dimensional printing technology. J Contemp Brachytherapy. Termedia Publishing; 2016 Jun; 8(3):208–14. https://doi.org/10.5114/jcb.2016.60679 PMID: 27504130

20. Laronda MM, Rutz AL, Xiao S, Whelan KA, Duncan FE, Roth EW, et al. A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice. Nature Communications. 2017 May 16; 8:15261. https://doi.org/10.1038/ncomms15261 PMID: 28509899